NASDAQ: SPRCScisparc Ltd Stock
$1.84-0.07 (-3.66%)
Updated Dec 12, 2025
SPRC Price
$1.84
Fair Value Price
N/A
Market Cap
$983.67k
52 Week Low
$1.55
52 Week High
$37.59
P/E
-0.66x
P/B
-4.1x
P/S
12.28x
PEG
N/A
Dividend Yield
N/A
Revenue
$284.36k
Earnings
$3.60M
Gross Margin
42.3%
Operating Margin
1,434.74%
Profit Margin
1,312.8%
Debt to Equity
-6.68
Operating Cash Flow
-$1M
Beta
0.78
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SPRC Overview
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SPRC's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SPRC
Ranked#434 of 487
Ranked#434 of 487
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $319.06 | A | |
| $15.85 | A | |
| $20.63 | A |
Be the first to know about important SPRC news, forecast changes, insider trades & much more!
SPRC News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SPRC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SPRC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SPRC is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
SPRC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more SPRC due diligence checks available for Premium users.
Valuation
SPRC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.66x
Industry
155.66x
Market
45x
SPRC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-4.1x
Industry
5.32x
SPRC's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
SPRC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SPRC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.5M
Liabilities
$1.5M
Debt to equity
-6.68
SPRC's short-term liabilities ($1.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SPRC's short-term assets ($843.25k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SPRC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SPRC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
SPRC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SPRC vs Biotech Stocks
Scisparc Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.